Latest Conference Articles

CRX100 plus a tumor-specific oncolytic vaccinia virus generated responses and was well tolerated in patients with recurrent, platinum-resistant ovarian cancer.

Durvalumab plus carboplatin and paclitaxel, followed by maintenance durvalumab with or without olaparib, showed improved efficacy vs chemotherapy alone in endometrial cancer.

Lenvatinib plus pembrolizumab did not best chemotherapy in pMMR endometrial cancer, but did offer a survival benefit in some subgroups of patients.

From key sessions at the 2024 SGO Annual Meeting to updates in the field, gynecologic oncology experts share their key takeaways from the meeting.

Christian Marth, MD, PhD, discusses the LEAP-001 trial of lenvatinib plus pembrolizumab vs chemotherapy in advanced or recurrent endometrial cancer.

Mansoor Raza Mirza, MD, discusses findings from part 2 of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial in primary advanced or recurrent endometrial cancer.

Reshma Mahtani, DO, spotlights the challenges women in oncology may face throughout their careers and gives some advice to those just starting out.

Kelly E. McCann, MD, PhD, discusses her career journey and evolving career aspirations as a woman in oncology.

ChatGPT may provide comprehensive and correct answers to genetic counseling questions for patients with gynecologic cancers.

Black patients with endometrioid endometrial carcinoma experienced an increased risk of death and lower enrollment in clinical trials vs White patients.

Judy Hayek, MD, discusses outcomes with minimally invasive vs open interval complete gross resection in patients with advanced ovarian cancer.

Leslie M. Randall, MD, MAS, discusses patient-reported outcomes from the ENGOT-cx11/GOG 3047/KEYNOTE-A18 trial in locally advanced cervical cancer.

Patients with perivascular epithelioid sarcoma of gynecologic or peritoneal origin experienced durable responses when treated with nab-sirolimus.

The activity of nab-sirolimus plus letrozole is under study in patients with advanced or recurrent endometrioid endometrial cancer.

Dimitrios Nasioudis, MD, discusses outcomes of patients with metastatic vulvar squamous cell carcinoma who underwent sentinel lymph node biopsy.

Sara Corvigno, MD, PhD, discusses the incidence of chemotherapy-related clonal hematopoiesis of indeterminate potential in patients with ovarian cancer.

Neoadjuvant tislelizumab in combination with chemotherapy was safe and produced responses in patients with locally advanced cervical cancer.

Mirvetuximab soravtansine improved health-related quality of life in patients with FRα-positive, platinum-resistant ovarian cancer.

Stereotactic ablative radiotherapy has shown clinical benefit in combination with immunotherapy in early-stage NSCLC, making it a viable treatment to consider.

Olaparib plus cediranib failed to improve PFS and OS vs chemotherapy in patients with platinum-resistant or -refractory epithelial ovarian cancer.

Dostarlimab plus carboplatin/paclitaxel improved overall survival vs placebo plus chemotherapy in primary advanced or recurrent endometrial cancer.

Quad Shot radiation plus a checkpoint inhibitor significantly improved local control vs Quad Shot alone and was well tolerated as a palliative treatment for patients with advanced head and neck cancer.

The addition of pembrolizumab to chemotherapy led to a favorable overall survival benefit vs chemotherapy plus placebo in endometrial cancer.

Social determinants of health were associated with geographical variations in the rates of cervical cancer in the United States.

I-Chia (Daniel) Liu, MD, discusses surgical and local control outcomes following short-course radiation therapy and chemotherapy for rectal cancer.

Robert W. Mutter, MD, discusses the nuances of partial breast irradiation in early-stage breast cancer.

A post-hoc analysis showed dose escalation of radiation therapy was safe and elicited similar efficacy in intrahepatic cholangiocarcinoma.

Charles B. Simone II, MD, FASTRO, FACRO, discusses advanced radiation techniques that could reduce cardiac toxicities.

James Knight, MD, discusses the potential launch of a case series of patients with brain-metastatic prostate adenocarcinoma.

Jason Efstathiou, MD, DPhil, discusses the role of tri-modality therapy in patients with muscle-invasive bladder cancer.